Cortez, Maria Angelica http://orcid.org/0000-0002-3130-4002
Masrorpour, Fatemeh
Ivan, Cristina http://orcid.org/0000-0002-4848-0168
Zhang, Jie
Younes, Ahmed I. http://orcid.org/0000-0002-1746-4624
Lu, Yue
Estecio, Marcos R
Barsoumian, Hampartsoum B.
Menon, Hari
Caetano, Mauricio da Silva
Ramapriyan, Rishab http://orcid.org/0000-0002-2945-3236
Schoenhals, Jonathan E.
Wang, Xiaohong
Skoulidis, Ferdinandos
Wasley, Mark D.
Calin, George http://orcid.org/0000-0002-7427-0578
Hwu, Patrick
Welsh, James W.
Funding for this research was provided by:
American Lung Association (RG-514395)
U.S. Department of Health & Human Services | National Institutes of Health (CA016672)
Article History
Received: 3 July 2019
Accepted: 26 August 2020
First Online: 24 September 2020
Change Date: 8 October 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: J.W.W. reports research support from GlaxoSmithKline, Bristol Meyers Squibb, Merck, Nanobiotix, Mavu Pharma, Takeda, Varian, and Checkmate Pharmaceuticals. J.W.W. serves on the scientific advisory board for Legion Healthcare Partners, RefleXion Medical, MolecularMatch, Merck, AstraZeneca, Aileron Therapeutics, Ventana, OncoResponse, CheckMate Pharmaceuticals, Mavu Pharma, Alpine Immune Sciences, and Nanorobotix. He is co-founder of Healios, MolecularMatch, and OncoResponse and serves as an advisor to Astra Zeneca, Merck, MolecularMatch, Incyte, Aileron, and Nanobiotix. J.W.W. holds stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, Healios, Mavu Pharma, Legion Healthcare Partners, MolecularMatch, Nanorobotix, OncoResponse, and RefleXion. J.W.W. has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian, Shandong University, The Korea Society of Radiology, Aileron Therapeutics and Ventana. J.W.W. has the following patents; MP470 (amuvatinib), MRX34 regulation of PDL1, XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopalTM. P.H. receives laboratory research support from Dragonfly, Immatics, Sanofi, and GlaxoSmithKline. All other authors declare no conflicts of interest.